Assessment of Interactions Between Methamphetamine and Aripiprazole - 1
NCT ID: NCT00089440
Last Updated: 2017-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
17 participants
INTERVENTIONAL
2004-06-30
2005-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aripiprazole for Methamphetamine Dependence: Double Blind Placebo Trial
NCT00728312
Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1
NCT00040040
Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1
NCT00033072
Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence
NCT02034201
Mirtazapine and Methamphetamine Drug-drug Interaction Study
NCT04614584
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aripiprazole
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures.
Exclusion Criteria
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Newton, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of California, Los Angeles
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States
New York University, School of Medicine
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIDA-MDS-0002-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.